In vitro inhibitory effect of lysionotin on the activity of cytochrome P450 enzymes

References

• Chang YP, Huang CC, Shen CC, Tsai KC, Ueng YF. 2015. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet. 30(5):374–383.
   PubMed Web of Science ®Google Scholar
• Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, et al. 2017. Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Xenobiotica. 47(9):778–784.
   PubMed Web of Science ®Google Scholar
• Chen JW, Zhu ZQ, Hu TX, Zhu DY. 2002. Structure-activity relationship of natural flavonoids in hydroxyl radical-scavenging effects. Acta Pharmacol Sin. 23(7):667–672.
   PubMed Web of Science ®Google Scholar
• Denisov IG, Grinkova YV, Nandigrami P, Shekhar M, Tajkhorshid E, Sligar SG. 2019. Allosteric interactions in human cytochrome P450 CYP3A4: the role of phenylalanine 213. Biochemistry. 58(10):1411–1422.
   PubMed Web of Science ®Google Scholar
• Galetin A, Gertz M, Houston JB. 2008. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol. 4(7):909–922.
   PubMed Web of Science ®Google Scholar
• Ge GB. 2019. Deciphering the metabolic fates of herbal constituents and the interactions of herbs with human metabolic system. Chin J Nat Med. 17(11):801–802.
   PubMed Web of Science ®Google Scholar
• Hao X, Yuan J, Xu Y, Wang Z, Hou J, Hu T. 2018. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica. 48(12):1185–1191.
   PubMed Web of Science ®Google Scholar
• He W, Wu JJ, Ning J, Hou J, Xin H, He YQ, Ge GB, Xu W. 2015. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol in Vitro. 29(7):1569–1576.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Clinical Pharmacogenetics Implementation Consortium, et al. 2015. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 98(2):127–134.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhang Z, Xia Y, Wang Z, Wang X, Wang S, Wang Z, Liu Y. 2020. Pterostilbene supplements carry the risk of drug interaction via inhibition of UDP-glucuronosyltransferases (UGT) 1A9 enzymes. Toxicol Lett. 320:46–51.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, Wang K, Chen D. 2017. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica. 47(10):849–855.
   PubMed Web of Science ®Google Scholar
• Liu H, Yan C, Li C, Lin L. 2013. LC-MS/MS determination of nevadensin in rat plasma and its application in pharmacokinetic studies. J Pharm Biomed Anal. 74:56–61.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang N, Li N, Fan X, Li Y. 2019a. Influence of verapamil on the pharmacokinetics of oridonin in rats. Pharm Biol. 57(1):787–791.
   PubMed Web of Science ®Google Scholar
• Liu L, Li P, Qiao L, Li X. 2019b. Effects of astragaloside IV on the pharmacokinetics of puerarin in rats. Xenobiotica. 49(10):1173–1177.
   PubMed Web of Science ®Google Scholar
• Liu L, Sun S, Rui H, Li X. 2017. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol. 55(1):1868–1874.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• Mano ECC, Scott AL, Honorio KM. 2018. UDP-glucuronosyltransferases: structure, function and drug design studies. Curr Med Chem. 25(27):3247–3255.
   PubMed Web of Science ®Google Scholar
• Ouyang DS, Huang WH, Chen D, Zhang W, Tan ZR, Peng JB, Wang YC, Guo Y, Hu DL, Xiao J, et al. 2016. Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chin Med. 11:11.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
   PubMed Web of Science ®Google Scholar
• Romand S, Spaggiari D, Marsousi N, Samer C, Desmeules J, Daali Y, Rudaz S. 2017. Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases. J Pharm Biomed Anal. 144:129–137.
   PubMed Web of Science ®Google Scholar
• Song J, Dai H, Zhang H, Liu Y, Zhang W. 2020. Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats. Xenobiotica. 50(5):602–605.
   PubMed Web of Science ®Google Scholar
• Suksamrarn A, Poomsing P, Aroonrerk N, Punjanon T, Suksamrarn S, Kongkun S. 2003. Antimycobacterial and antioxidant flavones from Limnophila geoffrayi. Arch Pharm Res. 26(10):816–820.
   PubMed Web of Science ®Google Scholar
• Teng Z, Shi D, Liu H, Shen Z, Zha Y, Li W, Deng X, Wang J. 2017. Lysionotin attenuates Staphylococcus aureus pathogenicity by inhibiting α-toxin expression. Appl Microbiol Biotechnol. 101(17):6697–6703.
   PubMed Web of Science ®Google Scholar
• Vrba J, Papoušková B, Lněničková K, Kosina P, Křen V, Ulrichová J. 2020. Identification of UDP-glucuronosyltransferases involved in the metabolism of silymarin flavonolignans. J Pharm Biomed Anal. 178:112972
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Xiao J, Chen D, Lin X-X, Peng S-F, Xiao M-F, Huang W-H, Wang Y-C, Peng J-B, Zhang W, Ouyang D-S, et al. 2016. Screening of drug metabolizing enzymes for the ginsenoside compound K in vitro: an efficient anti-cancer substance originating from Panax ginseng. PLoS One. 11(2):e0147183.
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem. 1(5):403–425.
   PubMedGoogle Scholar
• Yang J, Li Y, Li Y, Rui X, Du M, Wang Z. 2020. Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism. Xenobiotica. 50(6):685–688.
   PubMed Web of Science ®Google Scholar
• Yang K, Fu ZW, Cao YF, Li SN, Du Z, Sun XY, Liu YZ, Yang K, Fang ZZ. 2018. New insights for risks of chlorophenols (CPs) exposure: inhibition of UDP-glucuronosyltransferases (UGTs). Chemosphere. 206:9–16.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ya G, Rui H. 2017. Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet. 42(1):89–98.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, et al. 2007. Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci. 10(4):496–503.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang QY. 2012. Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine. J Pharmacol Exp Ther. 343(2):362–370.
   PubMed Web of Science ®Google Scholar